国药集团药业股份有限公司（以下简称"公司"）独立董事 2025 年第一次专门会议、第八届董事会第二十三次会议、第八届监事 会第十八次会议、2024 年年度股东大会审议通过了《国药股份 关于2024 年日常关联交易情况和预计2025 年日常关联交易的议 案》，对公司 2025 年所涉日常关联交易数额、关联方情况、定 1 重要内容提示： 本次增加 2025 年日常关联交易预计额度无需提交公司 股东会审议。 证券代码：600511 证券简称：国药股份 公告编号：临 2025-043 公司预计增加的 2025 年度日常关联交易为日常经营需 要，不存在损害公司和非关联方股东利益的情形，不影响公司独 立性。 国药集团药业股份有限公司 关于增加 2025 年日常关联交易预计额度的公告 一、日常关联交易基本情况 本公司董事会及全体董事保证本公告内容不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 （一）日常关联交易履行的审议程序 | 向关联人销售 | 国药控股四川医药股份 | 6,000.00 | 38,859.28 | 0.77 | | | --- | --- | --- | ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于国药集团药业股份有限公司 2025 年第四次临时股东会的 法律意见书 国枫律股字[2025]A0588 号 致：国药集团药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2025 年第四次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《国药集团药业股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律 ...

证券代码：600511 证券简称：国药股份 公告编号：2025-041 国药集团药业股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 12 月 9 日 (二)股东会召开的地点：北京市东城区永定门西滨河路 8 号院 7 楼中海地产广场 西塔 8 层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 228 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 466,351,992 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 61.8091 | (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由董事会召集，董事长刘月涛主持本次会议，会议采用现场投票和网络 投票的方式进行表决，符合《公司法》及《 ...

二、 董事会会议审议情况 本次会议审议并通过了如下决议： （一）以 9 票同意、0 票反对和 0 票弃权的结果审议通过《国 药股份关于调整第八届董事会专门委员会委员的议案》。 证券代码：600511 证券简称：国药股份 公告编号：临 2025-042 国药集团药业股份有限公司 第八届董事会第三十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 一、 董事会会议召开情况 国药集团药业股份有限公司（以下简称"公司"或"国药股 份"）第八届董事会第三十三次会议通知及资料于 2025 年 11 月 28 日以书面、电子邮件等形式发出，会议于 2025 年 12 月 9 日以 现场结合通讯表决方式召开。本次会议应到董事九名，实到董事 九名，其中四名独立董事参加了会议，董事长刘月涛先生主持本 次会议，部分高管列席会议，符合《公司法》和《公司章程》的 有关规定。 为加强董事会建设，提高董事会决策的科学性，充分发挥专 1 门委员会在上市公司治理中的作用，公司拟调整第八届董事会战 略委员会、提名委员会、审计委员会、薪酬与考核委 ...

Core Viewpoint - The launch of the China Drug Price Registration System marks a significant step towards a globalized pricing framework for innovative drugs, enhancing market-oriented pricing capabilities for pharmaceutical companies and supporting the development of a new pricing ecosystem that aligns drug prices with innovation value and market demand [1][2][6]. Group 1: Drug Price Registration System - The new system allows domestic and international pharmaceutical companies to independently register drug prices, ensuring accountability for price authenticity [1][3]. - The system operates under the principle of "one location acceptance, nationwide sharing, global openness," and is managed by a state-owned enterprise in Beijing [1][3]. - The first batch of companies to register prices includes major players such as China National Pharmaceutical Group, Beijing Tongrentang, and Roche, indicating strong industry participation [3]. Group 2: Impact on Pharmaceutical Industry - The system is expected to enhance the pricing strategies of pharmaceutical companies, allowing them to adjust prices based on clinical value, supply-demand dynamics, and competitive landscape [3][4]. - The dual mechanism of registration and query will promote transparency in drug pricing, moving away from previous opaque practices [4]. - The establishment of this system is anticipated to create a comprehensive pricing structure that encompasses innovative drugs, insurance payment prices, and generic drug prices, benefiting the innovative drug sector [5]. Group 3: Global Market Development - The China Drug Price Registration System is designed to facilitate the international expansion of Chinese innovative drugs and attract high-quality foreign drugs into the Chinese market [2][5]. - Data indicates that the total amount of overseas licensing transactions by Chinese pharmaceutical companies exceeded $92 billion in the first three quarters of 2025, highlighting the growing global presence of Chinese innovative drugs [2]. - The system aims to address significant price discrepancies between domestic and international markets, influenced by factors such as currency exchange rates and pricing mechanisms [5]. Group 4: Long-term Industry Implications - The implementation of the drug price registration system is expected to enhance the global competitiveness of China's biopharmaceutical industry and drive high-quality innovation within the sector [6].

Group 1 - The core viewpoint of the article is that He Yuan Bio has established a commercial partnership with China National Pharmaceutical Group (Sinopharm) and other distributors to enhance its market presence and product promotion [1] - He Yuan Bio has signed distribution agreements with multiple pharmaceutical distributors, including Sinopharm and Betta Pharmaceuticals, completing a sales network layout across over 30 provinces and cities in China [1] - Sinopharm acts as a commercial partner for He Yuan Bio in specific regions, focusing on academic promotion, market expansion, and channel development to jointly enhance product market coverage and clinical application [1]

Group 1 - The core viewpoint of the article highlights the collaboration between He Yuan Bio and China National Pharmaceutical Group (Sinopharm) as a commercial partner in specific regions, focusing on product promotion and market expansion [1] - He Yuan Bio has established a sales network across more than 30 provinces and cities in China through agreements with multiple distributors, including Sinopharm and Betta Pharmaceuticals [1] - The company is actively engaged in academic promotion, market development, and channel construction with Sinopharm to enhance product market coverage and clinical application [1]

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

国药集团药业股份有限公司 2025 年第四次临时股东会会议资料 股票代码：600511 2025 年 12 月 9 日 1 / 5 SH.600511 国药股份 2025 年第四次临时股东会议程 现场会议时间：2025 年 12 月 9 日 13:30 互联网投票平台网络投票时间： 2025 年 12 月 9 日 9:15-15:00 现 场会 议 地点 ： 北 京市 东 城区 永 定门 西 滨河 路 8 号 院 7 楼中海地产广场西塔 8 层会议室 会议议题： 一、审议关于选举董事的议案 2 / 5 SH.600511 一、审议关于选举董事的议案 交易系统平台网络投票时间： 2025 年 12 月 9 日 9:15-9:25，9:30-11:30，13:00-15:00； 公司于 11 月 21 日召开第八届董事会第三十二次会议，审议通过 了《关于提名董事候选人的议案》，提名黄国平先生（简历见附件） 为公司第八届董事会董事候选人。 以上议案提请股东会审议。 国药集团药业股份有限公司董事会 2025 年 12 月 9 日 4 / 5 SH.600511 附： 报告人：罗丽春 总法律顾问、董事会秘书 3 / 5 ...

Core Viewpoint - The increase in accounts receivable for China National Pharmaceutical Group Corporation (国药股份) is attributed to multiple factors, including business expansion, sales growth, and management strategies aimed at optimizing accounts receivable structure [1] Group 1: Factors Contributing to Accounts Receivable Increase - The company's business scale expansion and sales revenue growth have led to a corresponding increase in total accounts receivable [1] - The company is managing a dynamic balance between collection cycles and factoring discount costs, which has resulted in a reduction of the factoring scale for accounts receivable financing [1] - The collection cycles are also related to the periodic payment behaviors of clients, with some clients typically concentrating their payments at year-end [1] Group 2: Management Strategies - The company is committed to optimizing accounts receivable management through enhanced customer credit assessments and improved collection processes [1] - Measures are in place to ensure timely recovery of accounts receivable [1]